(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 3.85% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 134.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Amphastar Pharmaceuticals's revenue in 2025 is $723,305,000.On average, 8 Wall Street analysts forecast AMPH's revenue for 2025 to be $34,090,539,325, with the lowest AMPH revenue forecast at $32,268,995,148, and the highest AMPH revenue forecast at $35,328,490,893. On average, 8 Wall Street analysts forecast AMPH's revenue for 2026 to be $35,829,369,590, with the lowest AMPH revenue forecast at $32,725,759,758, and the highest AMPH revenue forecast at $38,633,830,769.
In 2027, AMPH is forecast to generate $37,143,601,766 in revenue, with the lowest revenue forecast at $33,639,748,498 and the highest revenue forecast at $40,240,318,772.